Wednesday, July 8, 2026

pharma · Becker Muscular Dystrophy · Muscular Dystrophies · EWTX

Edgewise Therapeutics

Edgewise Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker EWTX. Primary therapeutic focus areas include Becker Muscular Dystrophy, Muscular Dystrophies, Hepatic Impairme

1715 38th St., Boulder, CO 80301, US HQ
2017 Founded
154 Employees
Public company Type
EWTX · NYSE Ticker
Company details
Clinical program

EDG-7500

Phase 1 · small molecule · Healthy Adult Participants

EDG-7500 for Healthy Adult Participants is a Phase 1 program (small_molecule) at Edgewise Therapeutics with 1 ClinicalTrials.gov record(s).

← All Edgewise Therapeutics projects Phase 1 small molecule active

Internal code EDG-7500-107

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Edgewise Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Adult Participants
Status
active
Trials
1

Clinical trials